***Apologies for cross posting***
Future Science Group is pleased to announce that it is now fully compliant
with Athens authentication. This arrangement guarantees that customers
have maximum flexibility when accessing journal content via their robust
online platforms www.futuremedicine.com and www.future-drugs.com.
Future Science Groups support for the Athens Access Management System
means that users from academic centres and hospitals throughout the UK can
now benefit from access to Future Science Group content using Athens
Single Sign On (SSO) technology. This technology enables the use of the
same login credentials to access multiple information resources, so that
users can link seamlessly to other Athens SSO-protected information. By
offering support for all the major authentication standards, Athens allows
institutions the opportunity to evolve their authentication procedures at
their own pace.
Dr David Hughes, Publisher for the Future Science Group,
commented; ‘Developing a robust on-line platform for the dissemination of
published scholarly work is a constantly evolving task. By enabling
Athens authentication on our Future Drugs and Future Medicine websites, we
recognize the importance of developing our on-line presence to reflect the
needs of the academic & hospital sectors. As these needs evolve further
we will work to ensure that our on-line presence is at the forefront of
these developments. To this end, we are currently working to enable
Shibboleth authentication, and plan to role this feature out to end users
in 2007.’
The Future Science Group, incorporating Future Drugs and Future Medicine,
provides a critical mass of evaluated commentary in clinical medicine – 35
titles will deliver more than 3,000 reviews in 2007. Each title delivers
high-quality, evaluated and structured content from international opinion
leaders, with industry leading publication times.
For further information please contact:
Simon Boisseau
Marketing Manager
Future Science Group
[log in to unmask]
|